Prophylaxis of the antiphospholipid syndrome: A consensus report

Lupus

Volumn 12, Issue 7, 2003, Pages 499-503

  Alarcon Segovia D ^a   Boffa, M C ^b   Branch, W ^c   Cervera, R ^d   Gharavi, A ^e   Khamashta, M ^f   Shoenfeld, Y ^g   Wilson, W ^h   Roubey, R ⁱ  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^d HOSPITAL CLÍNIC   (Spain)

^e MOREHOUSE SCHOOL OF MEDICINE   (United States)

^f ST THOMAS HOSPITAL   (United Kingdom)

^g SHEBA MEDICAL CENTER   (Israel)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ NONE

Author keywords

Anti 2 glycoprotein; Anticoagulation; Antiphospholipid antibodies; Low dose aspirin; Pregnancy loss; Systemic lupus erythematosus; Thrombosis prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA CAROTENE; BETA GLOBULIN; CLOPIDOGREL; HYDROXYCHLOROQUINE; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PREDNISONE; WARFARIN;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; CONFERENCE PAPER; DRUG EFFECT; HIGH RISK PATIENT; HUMAN; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS PREVENTION;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLATELET AGGREGATION INHIBITORS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOSIS;

EID: 0038038390     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu388oa     Document Type: Conference Paper

References (9)

1. Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Do the benefits outweigh the risks? A decision analysis. Arch Int Med 2000; 160: 2042-2048.
2. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid antibody syndrome. New Engl J Med 1995; 332: 993-997.
3. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992, 117: 997-1002.
4. Erkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD. High thrombosis rate after fetal loss in APS: Effective prophylaxis with aspirin. Arthritis Rheum 2001; 44: 1466-1467.
5. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002; 41: 924-929.
6. Petri M, Hellman D, Hochberg M, Meyerhoff J, Bell W, Goldman D. Arterial thrombotic events in SLE: The Baltimore Lupus Cohort Study. Arthritis Rheum 1994; 37: S297 (abstract).
7. Gómez-Pacheco L, Villa AR, Drenkard C, Cabral AR, Alarcón-Segovia D. Serum anti-B2-glycoprotein-I antibodies during thrombosis in systemic lupus erythematosus patients. Am J Med 1999; 106: 417-423.
8. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors of thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood (in press).
9. Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, Tobar A, Shoenfeld Y. Bacterial induction of autoantibodies to B2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002; 109: 797-804.